Briefing
ADAPT-MRD opens a randomized comparison of ctDNA-guided adjuvant therapy after pancreatic resection
ClinicalTrials.gov lists ADAPT-MRD (NCT06966440) as a recruiting randomized trial that started June 1, 2025, assigning patients after resection of pancreatic cancer to ctDNA-guided adjuvant therapy or standard adjuvant therapy.